Despite Illumina's poor stock performance over the past two years, we believe it's an important competitively advantaged company and has become very undervalued. Illumina's sequencing instruments are ...

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO, March 14, 2023 /PRNewswire/ -- Illumina Inc.

Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, ...

SAN DIEGO — The unwinding of Illumina’s ill-fated acquisition of Grail earlier this year left investors and the genomics community with a pressing question: What kind of company is Illumina going to ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

The Advances in Genome Biology and Technology (AGBT) meeting celebrated its 25 th anniversary in sunny Marco Island, Florida, with the customary mix of big name speakers addressing researchers and ...

Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.

Sequencing giant Illumina Inc. ILMN is set to release third-quarter 2024 results on Nov. 4 after the closing bell. According to the Zacks Consensus Estimate, the company’s third-quarter earnings are ...